Table 3.
The Univariate and Multivariate Analyses of the Factors Associated with the Overalls Survival in Patients Receiving Pembrolizumab Treatment
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Variable | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | 0.998 (0.971–1.028) | 0.911 | |||
| Sex | Male | 1 | 1 | ||
| Female | 2.141 (1.244–3.687) | 0.006 | 1.544 (0.794–3.001) | 0.200 | |
| ECOG PS | 0 | 1 | 1 | ||
| 1 | 2.127 (1.173–3.855) | 0.013 | 1.820 (0.932–3.555) | 0.079 | |
| ≥2 | 8.654 (4.069–18.402) | <0.001 | 4.017 (1.618–9.975) | 0.003 | |
| Primary tumor site | Bladder | 1 | |||
| Upper urinary tract | 1.327 (0.728–2.419) | 0.356 | |||
| Bladder + upper urinary tract | 1.116 (0.544–2.287) | 0.765 | |||
| Histology | Pure UC | 1 | |||
| Mixed UC | 0.750 (0.367–1.534) | 0.431 | |||
| Albumin | ≥3.7 g/dl | 1 | 1 | ||
| <3.7 g/dl | 3.408 (1.959–5.929) | <0.001 | 2.744 (1.438–5.236) | 0.002 | |
| LDH | <246 U/L | 1 | 1 | ||
| ≥246 U/L | 2.135 (1.173–3.887) | 0.013 | 2.436 (1.228–4.829) | 0.011 | |
| Disease site (including primary organ) | 1 organ | 1 | 1 | ||
| 2 organs | 1.285 (0.599–2.757) | 0.519 | 2.093 (0.891–4.921) | 0.090 | |
| ≥3 organs | 2.772 (1.527–5.031) | <0.001 | 2.324 (1.149–4.702) | 0.019 | |
| Pretreatment REC | <4.8 | 1 | |||
| ≥4.8 | 1.000 (0.537–1.867) | 0.997 | |||
| Pretreatment NER | <13.7 | 1 | |||
| ≥13.7 | 1.142 (0.621–2.098) | 0.669 | |||
| Posttreatment REC (3 weeks later) | Increased | 1 | 1 | ||
| Decreased | 2.797 (1.643–4.763) | <0.001 | 31.298 (3.724–263.048) | 0.002 | |
| Posttreatment NER (3 weeks later) | Decreased | 1 | 1 | ||
| Increased | 2.254 (1.327–3.829) | 0.003 | 11.563 (1.430–93.481) | 0.022 | |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; UC, urothelial carcinoma; LDH, lactate dehydrogenase; REC, relative eosinophil count; NER, neutrophil-to-eosinophil ratio.